DPP-4 Inhibitors - Pharmacology Summary
Mechanisms ...

DPP-4 Inhibitors - Pharmacology Summary

Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1 and GIP.


 • Sitagliptin (Januvia) - Once/day tablet

 • Saxagliptin (Onglyza) - Once/day tablet

 • Linagliptin (Tradjenta) - Once/day tablet

Major Advantages: None specific


 • Recommended to avoid combination therapy with GLP-I receptor agonist

 • Personal history of pancreatitis

 • Saxagliptin is contraindicated in heart failure

Common Side Effects and Toxicities:

 • Joint pains, myalgias

 • Association with pancreatitis (though not definitively cause/effect)

 • Saxagliptin is associated with t risk of heart failure hospitalizations

- Dr. Eric Strong @DrEricStrong - Strong Medicine https://www.youtube.com/c/EricsMedicalLectures/featured

#DPP4 #Inhibitors #Pharmacology #Summary #DM2 #diabetes #endocrinology
Contributed by

Dr. Gerald Diaz
Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief 🇵🇭 🇺🇸 - Sign up for an account to like, bookmark and upload images to contribute to our community platform. Follow us on IG:  https://www.instagram.com/grepmed/ | Twitter: https://twitter.com/grepmeded/

Related content